Cost effectiveness and delivery study for future HIV vaccines: WHO-UNAIDS collaborative group on cost-effectiveness, delivery and future access to HIV vaccines

AIDS

Volumn 19, Issue 13, 2005, Pages

  Osmanov, Saladin ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Access; AIDS; Capacity; Cost effectiveness; Delivery; HIV; Immunization strategies; Policy; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG DELIVERY SYSTEM; FUTUROLOGY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 27944472025     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000181014.08127.a7     Document Type: Article

References (37)

1. UNAIDS. 2004 Report on the global AIDS epidemic. Geneva: WHO; 2004.
2. World Bank. Thailand Social Monitor: Thailand's response to AIDS: building on success, confronting the future. Bangkok: World Bank; 2000.
3. Stover J, Walker N, Garnett GP, Salomon JA, Stanecki KA, Ghys PD, et al. Can we reverse the HIV/AIDS pandemic with expanded response? Lancet 2002; 360:73-77.
4. UNAIDS and Thailand Ministry of Public Health. Evaluation of the 100% condom programme in Thailand. Geneva: WHO; 2000.
5. USAID, UNAIDS, WHO, UNICEF, and the POLICY Project. Coverage of selected services for HIV/AIDS prevention and care in low- and middle-income countries in 2003. Geneva: WHO; 2004.
6. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
7. Moatti JP, Spire B, Kazatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment:against a double standard between the north and the south. AIDS 2004; 18 (Suppl. 3):S55-S61.
8. Szekeres G, Coates TJ, Frost S, Leibowitz A, Shoptaw S. Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians. California: AIDS Partnership California and Center for HIV Identification, Prevention, and Treatment Services (CHIPTS); 2004. pp. 10-11.
9. Berman P. Preliminary results of the phase III efficacy trial of AIDSVAX B/B. Presented at: Keystone Symposium on HIV Vaccine Development. Banff, Canada, 2003.
10. Choopanya K, Tappero JW, Pitisuttithum P, Suntharasamai P, Kaewkungwal J, Vanichseni S, et al. Preliminary results of a phase III HIV vaccine efficacy trial among injecting drug users in Thailand. In: XVth International AIDS Conference. Bangkok, Thailand, 11-14 July 2004 [Abstract ThOrA1427].
11. Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 2004; 304:1913-1914.
12. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy anwers. Lancet Infect Dis 2004; 142:397-413.
13. Koopman JS, Little RJ. Assessing HIV vaccine effects. Am J Epidemiol 1995; 142:1113-1120.
14. Hudgens MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med 2003; 22:2281-2298.
15. Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacies and effectiveness aspects of vaccines. Am J Epidemiol 1997; 146:789-803.
16. Clements CJ, Chandra-Mouli V, Byass P, Ferguson BJ. Global strategies, policies and practices for immunization of adolescents: a review. WHO/V&B/99.24. Geneva: WHO; 1999.
17. McClure CA, Wright P, Rybczyk GK. Challenges to conduction of HIV preventive vaccine trials in adolescents. In: XIVth International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract TuPeD5058].
18. Chang ML, Vitek C, Esparza J. Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002. AIDS 2003; 17:W1-W10.
19. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000. AIDS 2001; 15: W27-W44.
20. An International Council of AIDS Service Organizations. Adding infrastructure to the advocacy agenda. A Project of the International Council of AIDS Service Organizations, Toronto, ON, Canada; 2002.
21. Canadian HIV/AIDS Legal Network. HIV vaccines in Canada: legal and ethical issues. Montreal; 2003.
22. Mahmoud A. The global vaccination gap. Science 2004; 305: 147.
23. Esparza J, Chang ML, Widdus R, Madrid Y, Walker N, Ghys PD. Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance. (A WHO/UNAIDS/IAVI study). Vaccine 2003; 21: 2032-2041.
24. International AIDS Vaccine Initiative. Delivering an AIDS vaccine. World Economic Forum Briefing Document. Geneva: WHO; 2002.
25. Warren M, Bass E. The correlates of readiness: getting the global house in order. Presentation to AIDS Vaccine 2004 International Conference. Lausanne, Switzerland, 2004.
26. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 1994; 265:1451-1454.
27. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet 1996; 348:1010-1013.
28. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr 2002; 29:132-141.
29. Stover J, Garnett GP, Seitz S, Forsythe S. The epidemiological impact of an HIV/AIDS vaccine in developing countries. Policy Research Working Paper 2811. Washington, DC: The World Bank; 2002.
30. van Ballegooijen M, Bogaards JA, Weverling GJ, Boerlijst MC, Goudsmit J. AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. J Acquir Immune Defic Syndr 2003; 34:214-220.
31. Barth-Jones DC, Longini IM. Determining optimal vaccination policy for HIV vaccines: a dynamic HIV model for use in developing and developed countries. Proceedings of the 2002 International Conference on Health Sciences Simulation. San Antonio, TX, 27-31 January 2002, pp. 63-79.
32. Barth-Jones DC, Chegulet BK, Longini, IM, Marum LM, Ackers ML, Essenmacher L, et al. Modeling the potential impact of a partially effective HIV vaccine in a generalized African HIV-1 epidemic: evaluating strategies for HIV vaccine use. Technical report 03-08. Atlanta, Georgia: Department of Biostatistics, Emory University; 2003.
33. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003; 23:76-82.
34. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18:3263-3282.
35. Surasiengsunk S, Kiranandana S, Wongboonsin K, Garnett GP, Anderson RM, van Griensven GJ. Demographic impact of the HIV epidemic in Thailand. AIDS 1998; 12:775-784.
36. Blower SM, Dowlatabadi H. Sensitivity and uncertainty and analysis of complex models of disease transmission: an HIV model as an example. Int Statist Rev 1994; 2:229-243.
37. Davenport MP, Ribeiro RM, Chao DL, Perelson AS. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 2004; 78:11340-11351.